Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02734602 · ClinicalTrials.gov registry record · NA

Imaging SV2A in Mood Disorders

A NA study of Major Depressive Disorder and Post Traumatic Stress Disorder, sponsored by Yale University.

Recruiting
Registry status
NA
Development phase
130
Enrollment target
1
Study location

NCT02734602: Recruiting NA study of Major Depressive Disorder and Post Traumatic Stress Disorder, sponsored by Yale University.

NCT02734602 is a NA study of Major Depressive Disorder and Post Traumatic Stress Disorder that is actively recruiting participants, run by Yale University. The registered enrollment target is 130 participants, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02734602, a NA study of Major Depressive Disorder and Post Traumatic Stress Disorder, is actively recruiting participants, sponsored by Yale University.

RECRUITING
Registry status
NA
Development phase
130 participants
Enrollment target
1
Study location

Study Summary

This study is designed to examine SV2A density in MDD and PTSD as a correlate of synaptic density, and to determine whether ketamine administration will reverse the synaptic loss in vivo in human subjects. To our knowledge, this is the first human study to examine SV2A in vivo in MDD and PTSD and to use the first known drug (ketamine) that rapidly reverses synaptic loss to determine whether ketamine administration could restore some of the structural changes associated with depression and PTSD. After a screening process to determine eligibility, all subjects will participate in an MRI, and 2-3 PET scans with the administration of ketamine for one of the scans. Cognitive testing and a stress test may also be done on scan days.

Interventions

  • DRUG Ketamine

Study Locations (1)

Connecticut

  • PET Center - New Haven

Trial Details

FieldValue
Enrollment Target 130 participants
Start Date 2016-04
Est. Completion 2027-03
Phase NA
Yale University

1,492 total trials

What NCT02734602 shows while recruiting

NCT02734602 is an interventional study that assigns participants to a tested intervention. The registered 130 participants enrollment target is mid-sized for trials with a published cap, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (65% lower).

The record links to 2 conditions, with Major Depressive Disorder appearing as the primary indexed condition, and to 1 intervention - of which Ketamine is the first listed.

NCT02734602 reports a single indexed study location in Connecticut.

Frequently Asked Questions

What is clinical trial NCT02734602 about?

NCT02734602 is a clinical study titled "Imaging SV2A in Mood Disorders". This study is designed to examine SV2A density in MDD and PTSD as a correlate of synaptic density, and to determine whether ketamine administration will reverse the synaptic loss in vivo in human subjects. To our knowledge, this is the first human study to examine SV2A in vivo in MDD and PTSD and to...

What is the current status of trial NCT02734602?

This trial is currently recruiting. It is a NA study. The enrollment target is 130 participants. The study started on 2016-04. Estimated completion is 2027-03.

What conditions does trial NCT02734602 study?

This clinical trial studies the following conditions: Major Depressive Disorder, Post Traumatic Stress Disorder.

What interventions are being tested in trial NCT02734602?

The interventions under investigation include: Ketamine (DRUG).

Who is sponsoring clinical trial NCT02734602?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02734602 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Major Depressive Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02734602's enrollment target sits among peer trials

130 113th of 282 higher than 170 of 282 other Major Depressive Disorder trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Major Depressive Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01492036 · 130 participants

    Long-Term Follow-Up of Recipient of Gene Transfer Research

  • NCT01631617 · 130 participants · Phase 2

    Effects of Treatments on Atopic Dermatitis

  • NCT02368041 · 130 participants

    Utility of Thenar Near Infrared Spectroscopy (NIRS) in Pediatric Patients With Heart Failure

  • NCT02604277 · 130 participants · NA

    Suicidal Behavior in Patients Diagnosed With Bipolar Disorder

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02734602, the US trial registry maintained by the National Library of Medicine. NCT02734602 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.